FTB Advisors Inc. maintained its position in Clorox Co. (NYSE:CLX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,567 shares of the company’s stock at the end of the second quarter. FTB Advisors Inc.’s holdings in Clorox were worth $217,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the company. Pictet Asset Management Ltd. boosted its stake in Clorox by 4.2% in the first quarter. Pictet Asset Management Ltd. now owns 194,556 shares of the company’s stock worth $24,596,000 after buying an additional 7,900 shares during the period. Quadrature Capital Ltd purchased a new stake in Clorox during the first quarter worth about $8,179,000. Scotia Capital Inc. boosted its stake in Clorox by 251.3% in the first quarter. Scotia Capital Inc. now owns 6,706 shares of the company’s stock worth $846,000 after buying an additional 4,797 shares during the period. Lazard Asset Management LLC boosted its stake in Clorox by 21.3% in the first quarter. Lazard Asset Management LLC now owns 164,652 shares of the company’s stock worth $20,755,000 after buying an additional 28,907 shares during the period. Finally, Optimum Investment Advisors boosted its stake in Clorox by 47.6% in the first quarter. Optimum Investment Advisors now owns 4,557 shares of the company’s stock worth $574,000 after buying an additional 1,470 shares during the period. 70.20% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Clorox Co. (NYSE:CLX) traded up 0.51% on Monday, reaching $122.39. 293,410 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $125.33 and its 200 day moving average price is $129.68. Clorox Co. has a 12 month low of $119.23 and a 12 month high of $140.47. The company has a market cap of $15.85 billion, a price-to-earnings ratio of 24.88 and a beta of 0.30.
Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.28 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Clorox had a return on equity of 296.91% and a net margin of 11.25%. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.44 earnings per share. Equities research analysts predict that Clorox Co. will post $5.49 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 14th. Stockholders of record on Wednesday, October 26th will be paid a dividend of $0.80 per share. The ex-dividend date is Monday, October 24th. This represents a $3.20 annualized dividend and a dividend yield of 2.62%. Clorox’s dividend payout ratio is presently 64.91%.
A number of research firms have issued reports on CLX. Zacks Investment Research upgraded shares of Clorox from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Goldman Sachs Group Inc. restated a “neutral” rating and set a $131.00 price target (up from $125.00) on shares of Clorox in a report on Friday, July 15th. Deutsche Bank AG restated a “hold” rating and set a $134.00 price target (up from $130.00) on shares of Clorox in a report on Sunday, July 24th. Citigroup Inc. upped their price target on shares of Clorox from $134.00 to $144.00 and gave the company a “neutral” rating in a report on Monday, August 8th. Finally, B. Riley restated a “neutral” rating and set a $109.00 price target on shares of Clorox in a report on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. Clorox presently has an average rating of “Hold” and a consensus price target of $127.80.
In other news, SVP Jon M. Balousek sold 5,136 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were sold at an average price of $131.14, for a total transaction of $673,535.04. Following the transaction, the senior vice president now directly owns 15,384 shares in the company, valued at approximately $2,017,457.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Nikolaos A. Vlahos sold 925 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $133.07, for a total transaction of $123,089.75. The disclosure for this sale can be found here. Insiders own 0.74% of the company’s stock.
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.